Refine by
Tumor Detection Articles & Analysis
28 news found
Tempus, a leader in artificial intelligence and precision medicine, today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM test and the xM (NeXT Personal® Dx) test by Personalis. The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help ...
ByTempus
The majority of precursor patients analyzed in the study showed evidence of CTCs, with one or more CTCs detected in 82% of the overall enrolled population-. In addition, the data showed an increase in the number of CTCs from MGUS to SMM, confirming the correlation between a higher disease burden and greater trafficking of CTCs. ...
Cancer Mutations within the entire exon region of cancerous genomes are more likely to induce tumor development. Accurate detection of SNV and InDel through whole exome sequencing can efficiently analyze cancer susceptibility and disease-causing genes, providing a reliable method for cancer genome research. ...
Cirdan are delighted to announce that together with Queen’s University Belfast and our KTP Associate and Senior AI Engineer, Jonathan Armstrong, we have been selected as the winners of the Best KTP project by Innovate UK. Innovate UK’s Best Knowledge Transfer Partnership award honours the KTP which has brought the greatest benefits to all three participants, exceeding the expectations ...
The funds will support the start of laboratory and clinical operations in the United-States focused on Prostate Cancer and Acute Myeloid Leukemia early detection tests. Rarecells leverages its proprietary ISET® Circulating Tumor Cells (CTC) platform, combined with cutting-edge downstream analyses, to generate a novel and powerful approach to ...
Cirdan are delighted to announce that together with Queen’s University Belfast and our KTP Associate and Senior AI Engineer, Jonathan Armstrong, we have been shortlisted for Innovate UK’s esteemed Best Knowledge Transfer Partnership Award. Innovate UK’s Best Knowledge Transfer Partnership award honours the KTP which has brought the greatest benefits to all three participants, ...
The USA boasts better cancer survival rates than most other developed countries. This was made possible due to a number of factors. In America, much attention is paid to medical equipment. Local oncology centers are equipped with the latest technology, actively use innovative technologies and new medicines. In addition, oncology in the United States involves extensive screening and more ...
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that clinical data from multiple internal and partnered programs were presented at the recent 2022 Annual Meeting of the American Academy of Ophthalmology (AAO), the world's largest association of eye ...
” Rarecells Inc. is a leading company in the development of innovative non-invasive tests for very Early Cancer Diagnosis based on a proprietary hypersensitive AI-based Circulating Tumor Cells (CTCs) and CTC-DNA detection. Founded in 2012, the firm is headquartered in New York and maintains offices and laboratories in New York and Paris. ...
This testing service will provide essential genomic information through comprehensive genomic profiling (CGP) for patients with any solid cancerous tumor. From a simple blood draw, the test identifies patients with actionable biomarkers more quickly than starting with tissue biopsy. ...
Creative Proteomics Cytokine recently announced the launch of the high-sensitivity Tumor Necrosis Factors (TNF) Detection Service to help with your TNF research. ...
Lost in the surgical backlog, already delayed diagnoses may be further delayed, potentially lowering patient outcomes. That’s why early detection is crucial; for patients with local to regional prostate cancer (PCa), the 5 year survival rate is nearly 100%, but drops to 30% once the cancer begins to spread to other organs.1 The current standard diagnostic pathway is a PSA ...
As of 2021, the American Cancer Society reports that Europe accounts for 22.8% of the world’s total cancer cases and 19.6% of cancer deaths, but currently, there are few local genomic providers of cancer detection and treatment monitoring that operate in the EU market. OncoDNA, amongst others, has been providing tissue-based biomarker testing and personalized liquid biopsy ...
It’s a scene that plays out daily in operating rooms around the world: a surgeon removes a malignant brain tumour. But rather than registering the satisfaction of having saved a patient’s life, hanging in the air is an all-too-real statistic; in 99.5% of these operations, unseen cancer cells remain. That hidden cancer will eventually grow and spread, and the operation will have become ...
Ambareen Sheriff appointed as Vice President, Regulatory and Quality and Robin Stevens appointed as Non-Executive Director Novel, best-in-class agent for visualizing breast cancer margins to enter Phase III trial in 1H22 SAN DIEGO, CA – Avelas Biosciences, Inc. (“Avelas” or “the Company”), a clinical-stage drug-device company pioneering the field of fluorescence ...
New study data presented at the European Congress of Cytology – held from 3-6 Oct in Warsaw, Poland – confirmed that X-ZELL is able to detect tumour-associated circulating atypical cells in the blood of lung cancer patients The dataset comprised interim results from a pilot study carried out in Thailand by X-ZELL and Dr Kittipong Maneechotesuwan from Mahidol University’s ...
“For example, we are seeing a higher percentage of dogs with early-stage rather than late-stage tumors than observed in normal practice. We think this may be due in part to the regular, six-month exams the dogs ...
ByCalviri
These tools are bringing real time tissue characterization to operating rooms and diagnostic suites, detecting the presence of invasive cancer directly in the patient during procedures. ...
Due to Bladder EpiCheck’s high sensitivity for high-grade disease and high specificity, and a well-planned infrastructure, all high-grade tumors, including muscle invasive tumors, were detected while avoiding 76% of unnecessary cystoscopies,” said Fred Witjes, M.D., Professor of Medical Sciences at Radboud University Medical Center. ...
” About Bladder EpiCheck® Bladder EpiCheck provides patients and clinicians with a simple, objective urine test to detect recurrence of bladder tumors. The test analyzes subtle disease-specific changes in DNA methylation markers, allowing for the detection of 92% of the high-risk (non Ta-LG) cancers. ...